volume 2, issue 8, PS452 2007
DOI: 10.1097/01.jto.0000283382.86209.a5
View full text
|
|
Share

Abstract: Background: In a national multicenter phase III study in stage IIIB and IV NSCLC patients, comparison of three cycles of vinorelbine/carboplatin (VC) to three cycles of gemcitabine/carboplatin (GC) concluded with equal survival in the two treatment arms. Hematological toxicity requiring interventions was more frequent in the GC arm but significant differences in quality of life (QOL) were not revealed. PS2 is the most powerful predictor of survival in patients with advanced NSCLC. Since single drug or combinat…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals